Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease worldwide. It is caused by mutations in the inflammasome adaptor Pyrin, but how FMF mutations alter signaling in FMF patients is unknown. Herein, we establish Clostridium difficile and its enterotoxin A (TcdA) as Pyrin-activating agents and show that wild-type and FMF Pyrin are differentially controlled by microtubules. Diverse microtubule assembly inhibitors prevented Pyrin-mediated caspase-1 activation and secretion of IL-1β and IL-18 from mouse macrophages and human peripheral blood mononuclear cells (PBMCs). Remarkably, Pyrin inflammasome activation persisted upon microtubule disassembly in PBMCs of FMF patients but not in cells of patients afflicted with other autoinflammatory diseases. We further demonstrate that microtubules control Pyrin activation downstream of Pyrin dephosphorylation and that FMF mutations enable microtubule-independent assembly of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) micrometer-sized perinuclear structures (specks). The discovery that Pyrin mutations remove the obligatory requirement for microtubules in inflammasome activation provides a conceptual framework for understanding FMF and enables immunological screening of FMF mutations.
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FMF | Pyrin | inflammasome | colchicine | microtubules I nflammasomes are multiprotein complexes that culminate in processing of caspase-1, thereby promoting maturation of proIL-1β and proIL-18 into their active forms (1) . Several inflammasome platforms have been described, and the concerted actions of inflammasomes frequently are of utmost importance for effective protection of the host against harmful environmental agents and infections (1) . Conversely, mutations in genes coding for inflammasome components and regulators cause debilitating systemic autoinflammatory diseases, of which cryopyrin-associated periodic syndromes (CAPS; NLRP3 mutations), autoinflammation with infantile enterocolitis (AIFEC; NLRC4 mutations), hyperimmunoglobulinemia syndrome (HIDS; MVK mutations) and familial Mediterranean fever (FMF; MEFV mutations) are notable examples (2, 3) .
FMF is the most common monogenic autoinflammatory disease worldwide, affecting an estimated 150,000 patients (4) . It typically has an autosomal recessive inheritance, and the clinical presentation is characterized by periodic fevers with childhood onset, frequently accompanied by serositis and joint pain (3, 4) . The disease is highly prevalent in populations of the Eastern Mediterranean basin and the Middle East and has spread to the rest of the world with the extensive migrations of these populations (4, 5) . More than 80% of FMF patients are homo-or (compound) heterozygous for mutations in MEFV, the gene that codes for the inflammasome adaptor Pyrin (4, 5) . More than 310 disease-associated variants in MEFV have been reported to date in the InFevers registry (6) , with most residing in the C-terminal B30.2 (PRY/SPRY) domain of human Pyrin. Importantly, however, how FMF mutations regulate Pyrin signaling has remained enigmatic, and mouse studies of FMF are complicated by the absence of the B30.2 domain in murine Pyrin.
FMF alleles occur in as many as one of every four individuals of non-Ashkenazi Jew, Arab, Armenian, and Turkish descent (7) (8) (9) (10) . In addition, a subset of FMF patients is heterozygous for disease-associated MEFV alleles, and the clinical/functional relevance of some MEFV alleles is debated. Consequently, genetic analysis of FMF is sometimes inconclusive, and FMF diagnosis may be delayed for years (11) . Although FMF is a systemic immunological disease, immunological diagnosis of the disease is currently not available and is likely to require further insight into how FMF mutations modulate Pyrin activation. The work presented Significance Familial Mediterranean fever (FMF) is an autoinflammatory disease caused by more than 310 mutations in the gene MEFV, which encodes Pyrin. Pyrin recently was shown to trigger inflammasome activation in response to Rho GTPase-modifying bacterial toxins. Here we report that Clostridium difficile infection and intoxication with its enterotoxin TcdA engage the Pyrin inflammasome. Moreover, activation of the Pyrin inflammasome, but not other inflammasomes, was hampered by microtubule-depolymerizing drugs in mouse and humans. Unexpectedly, we found that FMF mutations render Pyrin activation independent of microtubules. Thus, our findings provide a conceptual framework for understanding Pyrin signaling and enable functional diagnosis of FMF. here expands the set of Pyrin inflammasome-activating agents to live C. difficile infection and its enterotoxin TcdA. We further show that among the different known inflammasome sensors, wild-type Pyrin of both humans and mice relies selectively on microtubules for inflammasome activation. Microtubules control Pyrin signaling downstream of Pyrin dephosphorylation. Surprisingly, however, we found that FMF mutations lift the obligatory requirement for microtubules in activating the Pyrin inflammasome, providing a conceptual framework for understanding FMF and enabling immunological segregation of FMF from related autoinflammatory disorders.
Results
TcdA Activates the Pyrin Inflammasome in Mouse Macrophages and Human Monocytes. The Pyrin inflammasome responds to infection with Burkholderia cenocepacia (12, 13) and the Rho GTPasetargeting toxins Clostridium botulinum toxin C3 and C. difficile cytotoxin B (TcdB) in mouse macrophages (13) (14) (15) . Importantly, the B30.2 domain is absent in the murine Pyrin ortholog, which prompted us to characterize regulation mechanisms of Pyrin activation in peripheral blood mononuclear cells (PBMCs) of healthy donors in parallel with studies in murine bone marrow-derived macrophages (BMDMs). As reported (14, 15) , TcdB activated the Pyrin inflammasome in our studies ( Fig. S1 A and B) . C. difficile produces a second enterotoxin, C. difficile toxin A (TcdA), which exerts markedly different functions in disease models (16) . In examining the inflammasome response to TcdA, we found that apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), but not caspase-11, was required for caspase-1 maturation in LPS-primed BMDMs that had been incubated with TcdA (Fig. S1C) . Also, proteolytic conversion of proIL-1β into the mature cytokine required ASC and caspase-1 but not caspase-11 ( Fig. S1 C and D) . Consistent with TcdA activating a canonical inflammasome, extracellular release of IL-1β continued unabated in BMDMs lacking caspase-11 but was blunted in Asc −/− macrophages, in caspase-1
−/− BMDMs, and in macrophages of a newly generated caspase-1-deficient mouse strain ( Fig. S1D and Fig. S2 ). TcdA paralleled TcdB in engaging the Pyrin inflammasome because TcdA-induced caspase-1 activation and subsequent cleavage of proIL-1β were abolished in Pyrin (Mefv −/− ) BMDMs but not in Nlrp3 −/− macrophages (Fig. S1E ). Consistent with these findings, TcdA-intoxicated macrophages required Pyrin, but not Nlrp3, for secreting IL-1β (Fig. S1F) . These results demonstrate that TcdA selectively activates the Pyrin inflammasome in murine BMDMs. To examine whether this selective activation also occurs in humans, PBMCs from three healthy donors were incubated with the cell-permeable caspase-1 inhibitor Ac-YVAD-cmk or the Nlrp3 inflammasome-selective inhibitor MCC950/CRID3 (17, 18) before intoxication with TcdA. Pharmacological inhibition of caspase-1 significantly reduced TcdA-induced cleavage of proIL-1β and the extracellular release of IL-1β and IL-18 from human PBMCs (Fig. S1 G-I ). In contrast, TcdA-induced inflammasome activation was insensitive to MCC950/CRID3 at drug concentrations that effectively blunted Nlrp3-relayed IL-1β and IL-18 secretion from nigericin-treated PBMCs (Fig. S1 G-K). Thus, our results confirm recent findings that purified TcdA selectively engages the Pyrin inflammasome in mouse BMDMs (19) and extend these results to human PBMCs.
The Pyrin Inflammasome Is Engaged by C. difficile Infection. Both TcdA and TcdB contribute critically to C. difficile-induced pseudomembranous colitis (16) , although the pathogen also activates additional immune mechanisms independently of TcdA and TcdB (20) . Because microbial pathogens may express several virulence factors that engage multiple inflammasomes in parallel (21, 22) , and because the mechanisms of inflammasome activation induced by C. difficile infection are unknown, we next studied inflammasome responses in C. difficile-infected macrophages. Caspase-1 was activated in wild-type BMDMs infected with C. difficile, and this activation resulted in substantial cleavage and extracellular release of mature IL-1β ( Fig. S3 A and B) . These responses required live bacteria and the expression of the bacterial toxins TcdA and TcdB because inflammasome-dependent cytokine processing and secretion were blunted when BMDMs were exposed to heat-killed C. difficile or were infected with the TcdA/B-deficient (VP11186) C. difficile strain ( Fig. S3 A and B) . As with the purified toxins ( Fig.  S1 ), C. difficile infection-induced caspase-1 activation required Pyrin and the inflammasome adaptor ASC, whereas Nlrp3 and caspase-11 were dispensable ( Fig. S3 C and D) . Likewise, Mefv −/− and Asc
−/−
BMDMs failed to secrete IL-1β in the culture supernatants, whereas the supernatants of C. difficile-infected Nlrp3 −/− and caspase-11 −/− macrophages contained significant levels of IL-1β ( Fig.  S3 E and F) . Notably, caspase-1 was responsible for the gross amount of IL-1β maturation and secretion, but proIL-1β maturation and IL-1β secretion were not fully inhibited in caspase-1
−/− macrophages ( Fig. S3 C and E). These results suggest that additional proteases may, to a limited extent, contribute to Pyrinand ASC-dependent IL-1β secretion in C. difficile-infected macrophages. Regardless, C. difficile-infected PBMCs of healthy individuals also secreted high levels of IL-1β and IL-18, and these responses were inhibited by the cell-permeable caspase-1 inhibitor Ac-YVAD-cmk ( Fig. S3 G and H) . As in murine macrophages, C. difficile-induced inflammasome activation in human PBMCs was elicited by the bacterial toxins because IL-1β and IL-18 secretion was blunted upon infection with the TcdA/TcdB-deficient C. difficile mutant (Fig. S3 I and J) . Together, these results demonstrate that TcdA and TcdB are fully responsible for C. difficileinduced inflammasome activation in rodents and humans alike.
LPS Priming Is Dispensable but Enhances Pyrin Inflammasome Activation.
Having established that the enterotoxins are required for inflammasome activation induced by C. difficile infection, we next set out to investigate the mechanisms by which the enterotoxins engage the Pyrin inflammasome. We first asked whether Pyrin activation required priming, an important hallmark of the Nlrp3 inflammasome (23) . Both TcdA and TcdB triggered caspase-1 maturation in unprimed macrophages, indicating that Toll-like receptor (TLR) priming is not a prerequisite for the Pyrin inflammasome (Fig.  S4A ). ProIL-1β is produced only in response to NF-κB cues such as TLR ligands, whereas unprimed BMDMs express a constitutive pool of proIL-18 that is readily available for secretion upon inflammasome activation (24) . In agreement, culture medium of unprimed BMDMs secreted IL-18, but not IL-1β, when intoxicated with TcdA or TcdB (Fig. S4 B and C) . As expected, LPS priming supported the secretion of mature IL-1β by the two toxins (Fig.  S4B ) and further enhanced IL-18 secretion (Fig. S4C) . Notably, LPS priming also markedly enhanced the upstream activation of caspase-1 relative to levels seen in unprimed BMDMs (Fig. S4A) . These results suggested that LPS may increase Pyrin expression in BMDMs. Indeed, both a meta-analysis of public (25-29) microarray data (Fig. S4D ) and a longitudinal quantitative RT-PCR analysis of Pyrin expression levels showed that LPS increased Pyrin and Nlrp3 transcript levels by ∼10-fold in the first hours (Fig. S4 D  and E) . At 6 h after LPS stimulation, Pyrin levels had increased further to ∼30-fold over baseline levels, whereas Nlrp3 remained stable (Fig. S4E) . Collectively, these findings indicate that, although priming is not essential for Pyrin activation, it significantly enhances Pyrin inflammasome activation by TcdA and TcdB.
Microtubule-Depolymerizing Drugs Selectively Inhibit the Pyrin
Inflammasome. Ectopically expressed Pyrin partially associates with cytoskeletal structures (30) , but how this localization relates to its physiologic role in inflammasome activation is unclear. We found that neither inhibition of actin polymerization with cytochalasin D nor small-molecule targeting of downstream actin effectors (c-Abl kinase with STI-571, myosin II with myostatin, and Rock1/2 with Y-27632) interfered substantially with Pyrininduced IL-1β secretion from murine BMDMs and human PBMCs (Fig. S5 A and B) . Also the microtubule-stabilizing agent paclitaxel (taxol) failed to modulate the secretion of IL-1β and IL-18 from TcdA-treated PBMCs (Fig. S5 C and D) . In marked contrast, however, the microtubule polymerization inhibitor colchicine abolished caspase-1 maturation as well as downstream cleavage and secretion of IL-1β from TcdA-treated BMDMs (Fig. 1  A and B) . Lumicolchicine, a structurally related colchicine photoisomer that does not bind tubulin (31), did not affect Pyrin activation ( Fig. 1 A and B) , demonstrating the specificity of these results. Colchicine also abolished Pyrin-mediated IL-1β secretion from C. difficile-infected BMDMs (Fig. 1C) . Consistent with these results, colchicine, but not lumicolchicine, inhibited Pyrin-induced proIL-1β maturation in human PBMCs (Fig. 1D) and thus prevented the secretion of IL-1β and IL-18 from these cells (Fig. 1 E  and F) . Importantly, a set of structurally unrelated microtubule polymerization inhibitors (nocodazole, ABT-751, CA4P, and CYT997) also abolished the maturation of caspase-1, thereby hampering the ensuing cleavage and secretion of IL-1β from TcdAtreated BMDMs (Fig. 1 G and H) . Paralleling these results, these tubulin polymerization inhibitors prevented Pyrin-dependent IL-1β maturation in human PBMCs (Fig. 1I) . Similarly, secretion of IL-1β and IL-18 from TcdA-treated PBMCs was significantly reduced (Fig. 1 J and K) , establishing that microtubules are essential for human and murine Pyrin activation. These findings led us to examine the role of microtubule polymerization in other inflammasomes. Anthrax lethal toxin engaged Nlrp1b-dependent automaturation of caspase-1 and cleavage of proIL-1β regardless of whether BMDMs had been pretreated with colchicine (Fig. 1L) . Nlrc4-driven caspase-1 activation and intracellular IL-1β cleavage in Salmonella enterica serovar Typhimurium (S. Typhimurium)-infected macrophages also were normal in the presence of colchicine (Fig. 1M) , as was activation of the AIM2 inflammasome by transfected dsDNA (Fig. 1N) . Likewise, colchicine failed to modulate extracellular IL-1β release by each of these inflammasomes (Fig. S6  A-C) . Nigericin-induced Nlrp3 inflammasome activation in murine BMDMs and human PBMCs was insensitive to colchicine inhibition ( Fig. 1O and Fig. S6 D-F) , and nigericin-induced caspase-1 activation along with downstream maturation and release of IL-1β continued unabated in the presence of the microtubule polymerization inhibitors nocodazole, ABT-751, CA4P, and CYT997 (Fig. S7 ). In conclusion, polymerized tubulin selectively and Fig. 2 . Differential microtubule regulation of Pyrin inflammasome activation identifies FMF patients. (A) PBMCs from healthy donors (n = 7) and FMF patients (n = 2) were infected with C. difficile, and the supernatant was analyzed for IL-1β. (B) PBMCs from healthy donors (n = 3) and FMF patients (n = 2) were pretreated with Ac-YVAD-cmk before being stimulated with TcdA, and the supernatant was analyzed for IL-1β. (C and D) PBMCs from healthy donors (n = 7) and FMF patients (n = 2) were stimulated with LPS for 5 h (C) or were pretreated with colchicine before stimulation with TcdA (D), and the supernatant was analyzed for IL-1β. (E) PBMCs from healthy donors (n = 3) and FMF patients (n = 2) were pretreated with colchicine, nocodazole, ABT-751, CA4P, or CYT997 before stimulation with TcdA, and the supernatant was analyzed for IL-1β. (F and G) PBMCs from healthy donors (n = 5) and from CAPS (n = 4), JIA (n = 7), and FMF (n = 9) patients were pretreated with colchicine before stimulation with TcdA, and the supernatant was analyzed for IL-1β (F) and IL-18 (G). Luminex data are shown as mean ± SD, and all data are representative of at least three independent experiments. ns, non-significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. critically controls activation of the Pyrin inflammasome in humans and rodents alike. Because murine Pyrin lacks the C-terminal B30.2 domain of human Pyrin, these results also imply that this region is dispensable for inflammasome activation and colchicine regulation. Nevertheless, the great majority of FMF mutations in human Pyrin localize to the C-terminal B30.2 domain (4).
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Differential Microtubule Regulation of Pyrin Inflammasome Activation
Identifies FMF Patients. We therefore sought to determine how microtubules relate to Pyrin inflammasome signaling in FMF PBMCs. We reasoned that if microtubules relay an activating signal upstream of Pyrin, colchicine would halt TcdA-induced inflammasome activation in PBMCs of FMF patients. To test this hypothesis, we collected PBMCs from seven healthy controls and two FMF patients with confirmed MEFV mutations in the C-terminal B30.2 domain [ Table S1 , patients FMF1 (M694V/R761H) and FMF2 (M694I/M694I)]. We did not detect secreted IL-1β in culture supernatants of untreated PBMCs of healthy donors or FMF patients ( Fig. 2A) . C. difficile infection triggered a substantial but comparable release of IL-1β in wild-type and FMF PBMCs (Fig.  2A) . FMF PBMCs that had been intoxicated with TcdA also secreted normal levels of IL-1β, a response that was efficiently blocked by the caspase-1 inhibitor Ac-YVAD-cmk (Fig. 2B) . Moreover, IL-1β levels secreted by FMF PBMCs in response to the NLRP3 inflammasome stimulus LPS (32, 33) were comparable to those of healthy donors (Fig. 2C) . These results indicate that FMF mutations are not hypermorphic for inflammasome activation relayed by either Pyrin or NLRP3. Moreover, they suggest that FMF mutations differ from CAPS-linked mutations in NLRP3 that significantly enhance LPS-and cold-induced Nlrp3 inflammasome activation (33, 34) . Remarkably, however, although colchicine pretreatment abolished TcdA-induced IL-1β secretion from PBMCs of healthy individuals (Fig. 2D) , it augmented the TcdA-induced IL-1β secretion from FMF PBMCs (Fig. 2D) . The microtubule assembly inhibitors nocodazole, ABT-751, CA4P, and CYT997 also had opposite influences on TcdA-induced IL-1β secretion from FMF PBMCs and from PBMCs of healthy donors (Fig. 2E) . Furthermore, IL-18 release from TcdA-treated wild-type PBMCs was blunted by colchicine and other microtubule polymerization inhibitors, whereas FMF PBMCs resisted suppression (Fig. S8) . To validate these results further and to test whether resistance to colchicine inhibition was a defining feature of FMF PBMCs, we repeated our studies with PBMCs from a larger group of healthy donors (n = 5) and from an additional cohort of FMF were pretreated with colchicine before stimulation with TcdA and then were immunoblotted to detect phosphorylated Pyrin (S241), IL-1β, and β-actin (BMDMs), and phosphorylated Pyrin (S242), Flag, and tubulin (293T). PBMCs from healthy donors were pretreated with colchicine or CYT997 before stimulation with TcdA or nigericin (G and H). PBMCs from healthy donors and from CAPS, JIA, and FMF patients were pretreated with colchicine before stimulation with TcdA (I and J). ASC specks were analyzed by confocal microscopy as shown in micrographs (G and I) and automated quantification (H and J). Immunoblots and confocal images are representative of at least three independent experiments. ns, non-significant; ***P < 0.001; ****P < 0.0001.
patients with a variety of defined MEFV mutations (n = 9; Table  S1 ). PBMCs from patients afflicted with CAPS disease resulting from heterozygous mutations in NLRP3 (n = 4; Table S1 ) and from patients diagnosed with juvenile idiopathic arthritis (JIA, systemic and nonsystemic; n = 7) were tested also. As with PBMCs from healthy donors, colchicine blocked TcdA-induced IL-1β and IL-18 secretion from PBMCs of CAPS and JIA patients, indicating that their Pyrin inflammasome responses were regulated identically to those of healthy individuals (Fig. 2 F and G) . In marked contrast, however, all FMF patients continued to secrete significant IL-1β and IL-18 levels after colchicine pretreatment (Fig. 2 F and G) . We verified that colchicine efficiently disrupted assembled microtubules in the PBMCs of healthy individuals and FMF patients alike (Fig.  S9) , ruling out the remote possibility that microtubules of FMF PBMCs resisted microtubule disassembly by colchicine. Together, these results suggest that FMF mutations converge on lifting the critical requirement for microtubules in Pyrin inflammasome activation.
FMF-Associated Pyrin Binds Tubulin but Does Not Require Microtubules
for ASC Speck Assembly. Dephosphorylation of Pyrin's intermediate linker domain was recently shown to be required for TcdA-and TcdB-induced inflammasome activation (14, 15, 19) , and introduction of FMF mutations in the B30.2 domain of ectopically expressed Pyrin did not interfere with this process (15) . In agreement with these reports, we showed that endogenous Pyrin was not constitutively active in FMF PBMCs but was engaged only after TcdA stimulation or C. difficile infection ( Fig. 2 and Fig. S8 ). To characterize further how FMF mutations alter Pyrin-dependent inflammasome activation, we examined the binding of ectopically expressed Pyrin domains to endogenous tubulin (Fig. 3A) . Flag-fused constructs corresponding respectively to the N-terminal PYD domain, the intermediate linker sequence, the PYD+linker combination, or the C-terminal tripartite motif (TRIM) and B30.2 domains were expressed in 293T cells and were immunoprecipitated with Flagbeads. Constructs containing either the PYD or the C-terminal regions of wild-type Pyrin coprecipitated endogenous tubulin, but the intermediate linker sequence did not (Fig. 3B ). This result suggests that Pyrin interacts with tubulin through both its N and C termini. However, introduction of the FMF-associated M694V mutation did not prevent tubulin binding in either full-length Pyrin (Fig. 3C ) or in the isolated carboxyl-terminal region (Fig. 3D ). As reported (19) , TcdA also triggered Pyrin dephosphorylation in wild-type BMDMs that had been pretreated with colchicine (Fig. 3E) . Furthermore, colchicine failed to prevent TcdA-induced dephosphorylation of ectopically expressed wild-type Pyrin and the FMF-associated M694V Pyrin mutant in 293T cells (Fig. 3F ). In agreement with our other studies showing that microtubule polymerization inhibitors prevented inflammasome activation selectively in wildtype, but not in FMF, PBMCs, this finding positions microtubules in the pathway downstream of Pyrin dephosphorylation. PYD-based inflammasome sensors such as Pyrin nucleate ASC filaments through a biphasic mechanism in which their PYD domain first nucleates ASC PYD to oligomerize into prion-like fibers that then condense into ASC specks through ASC-caspase recruitment domain (CARD) interactions that also enable the recruitment of caspase-1 zymogens (35) . Interference with these first and second stages of ASC speck assembly therefore results in either the complete absence or the formation of atypical filamentous fibers, respectively (35) . We exposed PBMCs of healthy donors to TcdA or nigericin to trigger ASC speck assembly through the Pyrin and NLRP3 inflammasomes, respectively (Fig. 3 G and  H) . Colchicine and the unrelated microtubule polymerization inhibitor CYT997 selectively prevented ASC speck formation in response to TcdA but not in nigericin-treated PBMCs (Fig. 3 G and  H) , demonstrating that microtubules were selectively required for nucleation of ASC specks by Pyrin but not by NLRP3. As in healthy donors, colchicine abolished TcdA-induced ASC speck assembly in PBMCs of CAPS and JIA patients (Fig. 3 I and J) . In marked contrast, however, the assembly of ASC specks by FMF PBMCs was unabated in the presence of colchicine (Fig. 3 I and J) . Similar results were obtained with the unrelated microtubule polymerization inhibitor CYT997 (Fig. S10) . Thus, FMF mutations in Pyrin remove the critical dependency on microtubules for ASC speck assembly and inflammasome activation downstream of Pyrin dephosphorylation.
Discussion
The observation that Pyrin inflammasome activation by TcdA, TcdB, and live C. difficile infection required intact microtubules in both human PBMCs and murine macrophages implies that the C-terminal B30.2 domain, which harbors most FMF mutations in humans but is absent in mouse Pyrin, is dispensable for inflammasome activation. Although the B30.2 domain is dispensable for Pyrin inflammasome activation, we established here that FMF mutations in this domain nonetheless remove the critical reliance on intact microtubules for Pyrin-based nucleation of ASC specks and inflammasome signaling. Microtubules were recently proposed to control inflammasome activation apically of Pyrin dephosphorylation in response to bacterial RhoA inactivation (14) . However, this suggestion is difficult to reconcile with the observation that TcdAinduced Pyrin dephosphorylation continued unhampered in colchicine-pretreated macrophages and 293T cells (Fig. 3 E and  F and ref. 19) . Moreover, we showed that FMF mutations render Pyrin activation independent of microtubules. Thus, our results provide a conceptual framework for understanding FMF based on a mechanistic model of Pyrin signaling in which microtubules control inflammasome activation downstream of Pyrin dephosphorylation (Fig. 4) (Fig. 4) .
Paradoxically, although we show here that FMF mutations render Pyrin inflammasome activation insensitive to colchicine, this drug is an effective treatment that suppresses periodic inflammatory attacks in the majority of FMF patients and prevents amyloidosis, a major long-term complication of the disease that may result in renal failure and death (5, 36) . However, the clinical efficacy of colchicine treatment is likely associated with its ability to decrease leukocyte motility and phagocytosis during inflammation (37, 38) . Recent studies suggested that defects in the mevalonate pathway seen in the hereditary autoinflammatory disease mevalonate kinase deficiency (MKD), also named "hyperimmunoglobulinemia D syndrome" (HIDS), may also trigger unwarranted activation of the Pyrin inflammasome (14, 39) . In contrast to FMF patients, however, MKD patients generally do not benefit from colchicine treatment, whereas blockade of IL-1 has shown promising results (40) . Given our observations that FMF mutations render Pyrin activation resistant to colchicine blockade, it would be interesting to investigate the role of microtubules in MKDassociated inflammasome activation.
Akin to colchicine, certain pathogens express toxins that manipulate microtubule dynamics, as exemplified by the CDT toxin of hypervirulent C. difficile strains (41) . It therefore is tempting to speculate that the high frequency of heterozygous MEFV mutations in endemic FMF regions (42) might be related to their rendering Pyrin activation insensitive to microtubule manipulations by such pathogens. Given the key role of inflammasomes in antimicrobial host defense (43) , the ability to engage the Pyrin inflammasome in the presence of microtubule dynamics blockade is likely to have offered heterozygous individuals a selective advantage in clearing such infections. Finally, the insight that inflammasome activation by FMF Pyrin resists colchicine blockade enables functional/immunological screening of the disease among clinically overlapping autoinflammatory patients and thus may contribute to timely diagnosis and commencement of therapy in the future.
Materials and Methods
All reported patients and healthy controls provided written informed consent for participation in the study, in accordance with International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (ICH/GCP) guidelines. The research protocol was approved by the ethics committee of Ghent University Hospital under number 2012_593 and the protocols of Bambino Gesù Children's Hospital.
All mice were kept in specific pathogen-free conditions within the animal facilities of Ghent University. All animal experiments were approved by the ethics committee on laboratory animal welfare of Ghent University.
Detailed methods used in all experiments throughout this work are described in SI Materials and Methods.
